New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:35 EDTWX, ILMNWuXi PharmaTech purchases Illumina HiSeq X Ten Sequencing System
Illumina (LMN) and WuXi PharmaTech (WX) announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi’s clinical genomic services to expand from the current target panel, exome, and transcriptome scale sequencing to population genome scale sequencing. It puts the world’s most advanced gene sequencing capability in the hands of the leading pharmaceutical R&D services company in the Asia Pacific region. The WuXi Genome Center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.
News For WX;ILMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
08:26 EDTWXWuXi PharmaTech launches office in Israel and partners with Israel's Pontifax
WuXi PharmaTech established a representative office in the Tel Aviv area of Israel. The new office will also collaborate with Pontifax, a healthcare-dedicated venture capital firm based in Israel, to invest in promising technologies in Israel.
October 23, 2014
16:48 EDTWXWuXi PharmaTech acknowledges partner TaiMed Biologics for orphan designation
WuXi PharmaTech congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients. "We commend TaiMed's great progress in advancing this important life-saving therapy," said Dr. Ge Li, Chairman and CEO of WuXi. "This is the first biologic manufactured in China to receive Orphan Drug Designation, a historic milestone for TaiMed, for WuXi, and also for China."
October 22, 2014
11:34 EDTILMNLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:22 EDTWXFoundation Medicine, WuXi PharmaTech announce strategic collaboration
Foundation Medicine (FMI) and WuXi PharmaTech (WX) announced a collaboration to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
08:13 EDTWXFoundation Medicine, WuXi PharmaTech announce collaboration
Subscribe for More Information
October 21, 2014
12:57 EDTILMNOn The Fly: Midday Wrap
Subscribe for More Information
10:00 EDTILMNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:15 EDTILMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Apple (AAPL), up 3%... Texas Instruments (TXN), up 2.3%... Harley Davidson (HOG), up 7%... Celanese (CE), up 4%... United Technologies (UTX), up 1.4%. ALSO HIGHER: Neonode (NEON), up 20% after signing technology development agreement with global tier-one printer OEM... Illumina (ILMN), up 10%, upgraded at Janney Capital following the company's better than expected Q3 earnings. DOWN AFTER EARNINGS: Coca-Cola (KO), down 5%... Chipotle (CMG), down 4.6%... Verizon (VZ), down 1%. ALSO LOWER: CEL-SCI (CVM), down 15.3% after announcing proposed offering of common stock, warrants... Omeros (OMER), down 12% after suspending Huntington's clinical trial with OMS824... Tesoro Logistics (TLLP), down 2.4% after 20M share secondary priced at $57.47... Rhino Resources (RNO), down 53%, downgraded to Underperform at Raymond James following the reduction in its quarterly cash dividend.
07:52 EDTILMNIllumina upgraded to Buy at Janney Capital
As reported previously, Janney Capital upgraded Illumina to Buy from Neutral citing its Q3 earnings beat and checks indicating next generation sequencing competition remains sidelined as the company's competition focuses on diagnostics. Janney raised its fair value estimate on the stock to $192 from $165.
07:22 EDTILMNIllumina upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
06:16 EDTILMNIllumina price target raised to $210 from $192 at Piper Jaffray
Piper Jaffray raised its price target for Illumina shares to $210 following the company's better than expected Q3 results and increased guidance. Piper views the new guidance as achievable and keeps an Overweight rating on the stock.
October 20, 2014
18:51 EDTILMNOn The Fly: After Hours Movers
Subscribe for More Information
16:51 EDTILMNIllumina up 9.8% after reporting Q3 results
Subscribe for More Information
16:13 EDTILMNIllumina trades higher after results, first look
Subscribe for More Information
16:11 EDTILMNIllumina raises FY14 EPS view to $2.63-$2.65, consensus $2.30
Raises FY14 revenue growth view to approximately 30% YoY, consensus $1.8B. Prior view was $2.26-$2.28 for EPS and 25%-26% for revenue growth. Cites strong year to date results.
16:09 EDTILMNIllumina reports Q3 gross margin 69.5% vs. 58.8% in prior year period
Subscribe for More Information
16:09 EDTILMNIllumina reports Q3 adjusted EPS 77c, consensus 56c
Subscribe for More Information
15:30 EDTILMNNotable companies reporting after market close
Subscribe for More Information
07:11 EDTILMNAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTWX, ILMNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use